Given that RalA overexpression shortens the lifespan of the CML mice model, we analyzed the role of RalA in regulating imatinib and ponatinib sensitivity in CML cells. The gene discussed is RALA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.